PR91385

LONDON, Aug. 30, 2021 /PRNewswire=KYODO JBN/ --

    - Four GARFIELD-AF e-posters shine light on managing atrial fibrillation

(AF) in patients with clinically challenging conditions and diabetes, as well

as on AF trial populations

    - Two RIVER e-posters provide two-year outcomes data and insights on

appropriate dosing and renal function in patients with AF and treated with

rivaroxaban

    The Thrombosis Research Institute (TRI) has six atrial fibrillation

e-posters – four from the GARFIELD-AF Registry and two from the RIVER Registry

– at the European Society of Cardiology (ESC) Congress 2021, which is taking

place virtually from 27th to 30th August 2021.

    "We are delighted once again to have a strong showing at ESC Congress

2021," said Rt. Hon. Professor the Lord Ajay Kakkar, Director of the TRI.

"While these two real-world registries have closed, we continue to mine the

data and provide important insights that help clinicians around the world

manage patients with atrial fibrillation and achieve better outcomes."

    One of the GARFIELD-AF posters about clinically challenging conditions is

of key importance to current practice since it sheds light on treatment in

patients who physicians are concerned about treating. One of the RIVER posters

looks at dosing, and shines a light on the issue of non-recommended dosing in

patients based on renal function.

    Two other GARFIELD-AF posters demonstrate how similar the populations in

the trials studied are to the general AF population and confirm whether similar

results are observed when these patient populations are replicated. This is

important because these findings give credence to the generalisability of the

trials.

All of the TRI e-posters are available for registered participants to view on

the ESC Congress 2021 Research Gateway

[https://esc2021-abstract.medicalcongress.online/] platform at any time 'on

demand'. The full list of e-posters is below:

Presenter                        E-Poster Title                          

                                               GARFIELD-AF Registry

Professor Jean-Pierre Bassand (University Hospital Jean Minjoz - Besancon,

France)  Impact of NOAC and VKA on outcome of patients with newly diagnosed

atrial fibrillation and diabetes: A report from the GARFIELD-AF Registry

Saverio Virdone (Thrombosis Research Institute - London, United Kingdom)

Comparative effectiveness of NOAC vs VKA in patients representing common

clinical challenges: results from the GARFIELD-AF registry

Dr Jelle Caspar Lorenz Himmelreich (Amsterdam University Medical Center -

Amsterdam, Netherlands) Safety and efficacy of apixaban and rivaroxaban versus

warfarin in real-world atrial fibrillation patients are similar to their

randomized trials: insights from GARFIELD-AF registry

Dr Jelle Caspar Lorenz Himmelreich (Amsterdam University Medical Center -

Amsterdam, Netherlands) Comparing Rivaroxaban and Apixaban in GARFIELD-AF

according to ROCKET AF and ARISTOTLE trial selection criteria  

                                                RIVER Registry

Associate Professor Jan Beyer-Westendorf (University Hospital "Carl Gustav

Carus" Dresden, Center for Vascular Medicine - Dresden,Germany)                

Two-year outcomes of patients with atrial fibrillation treated with    

rivaroxaban: results from RIVER registry

Professor John Camm (St George's University of London - London, United Kingdom)

Rivaroxaban dosing in patients with atrial fibrillation: results  from the

RIVER registry - is dosing according to renal function appropriate?

About GARFIELD-AF

The GARFIELD-AF registry was a worldwide observational study of stroke

prevention in patients with newly diagnosed atrial fibrillation, coordinated

under the auspices of the Thrombosis Research Institute between 2009 and 2019.

GARFIELD-AF recruited patients with newly diagnosed non-valvular AF and at

least one risk factor for stroke. A total of 57,262 patients were recruited

from over 1,000 centres in 35 countries worldwide, including the Americas,

Europe, Africa and Asia-Pacific, over five sequential cohorts. Follow-up was

over a minimum of 2 years and up to 8 years after diagnosis, to create a

comprehensive database of treatment decisions and outcomes in everyday clinical

practice.

GARFIELD-AF is supported by KANTOR CHARITABLE FOUNDATION for the Kantor-Kakkar

Global Centre for Thrombosis Science. For more information, visit our website:

www.garfieldregistry.org.

About RIVER

The RIVER registry was a pioneering, independent outcomes research initiative

focused on the use of rivaroxaban and the management of atrial fibrillation and

stroke, led by an international steering committee under the auspices of the

Thrombosis Research Institute between 2015 and 2019.

RIVER recruited over 5,000 patients with newly diagnosed non-valvular AF and at

least one risk factor for stroke. Patients were recruited over a period of

18-24 months. The follow-up period was for a minimum of 2 years, to create a

comprehensive database of treatment decisions and outcomes in everyday clinical

practice.

RIVER is supported by KANTOR CHARITABLE FOUNDATION for the Kantor-Kakkar Global

Centre for Thrombosis Science. For more information, visit our website:

https://www.riverregistry.org/.

The burden of AF

Up to 2% of the global population has AF,i including around 8.8 million people

in Europeii and 5–6.1 million in the United States.iii It is estimated that its

prevalence will at least double by 2050 as the global population ages.iii AF is

associated with a five-fold increase in stroke risk, and one out of five

strokes is attributed to this arrhythmia.i Ischaemic strokes related to AF are

often fatal, and those patients who survive are left more frequently and more

severely disabled and have a greater risk of recurrence than patients with

other causes of stroke.i Hence, the risk of mortality from AF-associated stroke

is doubled and the cost of care is 50% higher.i

AF occurs when parts of the atria emit uncoordinated electrical signals. This

causes the chambers to pump too quickly and irregularly, not allowing blood to

be pumped out completely.iv As a result, blood may pool, clot and lead to

thrombosis, which is the number one cardiovascular killer in the world.v If a

blood clot leaves the left atrium, it could potentially lodge in an artery in

other parts of the body, including the brain. A blood clot in an artery in the

brain leads to a stroke; 92% of fatal strokes are caused by thrombosis.v Stroke

is a major cause of death and long-term disability worldwide – each year, 5.5

million people dievi and 5 million are left permanently disabled.vii People

with AF also are at high risk for heart failure, chronic fatigue and other

heart rhythm problems.viii

About the TRI

The TRI is dedicated to bringing new solutions to patients for the detection,

prevention and treatment of blood clots. The TRI's goal is to advance the

science of real-world enquiry so that the value of real-world data is realised

and becomes a critical link in the chain of evidence. Our pioneering research

programme, across medical disciplines and across the world, continues to

provide breakthrough solutions in thrombosis. For more information, visit:

http://www.tri-london.ac.uk/.

--------------------------------------------------------------------------------

i Camm A J, Kirchhof P, et al. Guidelines for the management of atrial

fibrillation: The Task Force for the Management of Atrial Fibrillation of the

European Society of Cardiology (ESC). Eur Heart J 2010; 31(19):2369-429.

ii Krijthe B P, Kunst A, et al. Projections on the number of individuals with

atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;

34:2746-51.

iii Colilla S, Crow A, Petkun W, et al. Estimates of current and future

incidence and prevalence of atrial fibrillation in the U.S. adult population.

Am J Cardiol 2013; 112(8):1142-7.

iv National Heart, Lung, and Blood Institute. What is Atrial Fibrillation?

Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/af/.

Accessed:  August 2021.

v World Thrombosis Day. Know Thrombosis. Available at:

http://www.worldthrombosisday.org/issue/thrombosis/. Accessed: August 2021.

vi World Stroke Organization. Learn about stroke. Available at:

https://www.world-stroke.org/world-stroke-day-campaign/why-stroke-matters/learn-about-stroke.

Accessed: August 2021.

vii World Health Organization. Global burden of stroke. Available at:

https://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf.

Accessed: August 2021.

viii American Heart Association. Why Atrial Fibrillation (AF or AFib) Matters.

Available at:

https://www.heart.org/en/health-topics/atrial-fibrillation/why-atrial-fibrillation-af-or-afib-matters.

Accessed: August 2021.

Source: Thrombosis Research Institute (TRI)